Delliere presented data from a retrospective observational study that showed a steady increase in female speakers at ESCMID Global between 2016 and 2023. This positive increase continued at ESCMID ...

ESCMID Global 2025 delivered a compelling call to action: use evidence to shape clinical care. From diabetes and cancer to administration options and drug-resistant pathogens, the sessions reinforced ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria.

基于此，一场感染病领域的学术盛宴在奥地利维也纳拉开了帷幕——欧洲临床微生物学与感染病学会全球大会（ESCMID Global 2025），于2025年4月11-15日盛大举行。

Furthermore, despite a slow decrease in the global incidence of viral hepatitis B (HBV) and C (HCV) in recent years, mortality due to these viruses has been increasing. In 2016, WHO launched the ...

Allschwil, Switzerland, April 16, 2025. Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe ...

Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025 Provided by GlobeNewswire Apr 16, 2025 5:15am Allschwil ...

ESCMID represents the European Society of Clinical Microbiology and Infectious Diseases. At the ESCMID Global 2025 conference in Vienna, Austria, held April 11-15, 2025, a total of over 7,800 abstract ...